Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
Authors
Keywords
-
Journal
Clinical and Translational Gastroenterology
Volume 7, Issue 1, Pages e135-e135
Publisher
Springer Nature
Online
2016-01-08
DOI
10.1038/ctg.2015.63
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy
- (2015) Andres J. Yarur et al. Clinical Gastroenterology and Hepatology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn’s Disease: Avoiding Failure While Lowering Costs?
- (2015) Niels Vande Casteele et al. DIGESTIVE DISEASES AND SCIENCES
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance - progress and prospects
- (2014) G. R. Jones et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?
- (2014) Shomron Ben-Horin DIGESTIVE DISEASES
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study
- (2013) Monica Cesarini et al. DIGESTIVE AND LIVER DISEASE
- Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases
- (2013) Anthony Lopez et al. INFLAMMATORY BOWEL DISEASES
- Dose optimization of infliximab in patients with rheumatoid arthritis
- (2013) Rieke Alten et al. International Journal of Rheumatic Diseases
- Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy
- (2013) Michael Sherman et al. Journal of Digestive Diseases
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response
- (2012) Lior Katz et al. INFLAMMATORY BOWEL DISEASES
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease
- (2011) Jean-Frédéric Colombel et al. INFLAMMATORY BOWEL DISEASES
- Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
- (2011) Michael B. Sprakes et al. Journal of Crohns & Colitis
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- 5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis
- (2010) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
- (2010) S. Ben-Horin et al. GUT
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Adherence to adalimumab therapy in Crohnʼs disease: A French multicenter experience
- (2010) Vincent Billioud et al. INFLAMMATORY BOWEL DISEASES
- Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
- (2010) Matthieu Allez et al. Journal of Crohns & Colitis
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
- (2007) Mark A. Ainsworth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More